The document discusses the development of an indigenous hepatitis B vaccine in India. It describes how the vaccine was developed using recombinant DNA technology by inserting the HBsAg gene into yeast cells. This allows the yeast to produce particles similar to the hepatitis B virus. Clinical trials showed the indigenous yeast-derived vaccine to be safe and effective while being a third of the cost of imported vaccines. India thus became the fourth country to develop an advanced hepatitis B vaccine domestically.
The document discusses the development of an indigenous hepatitis B vaccine in India. It describes how the vaccine was developed using recombinant DNA technology by inserting the HBsAg gene into yeast cells. This allows the yeast to produce particles similar to the hepatitis B virus. Clinical trials showed the indigenous yeast-derived vaccine to be safe and effective while being a third of the cost of imported vaccines. India thus became the fourth country to develop an advanced hepatitis B vaccine domestically.
The document discusses the development of an indigenous hepatitis B vaccine in India. It describes how the vaccine was developed using recombinant DNA technology by inserting the HBsAg gene into yeast cells. This allows the yeast to produce particles similar to the hepatitis B virus. Clinical trials showed the indigenous yeast-derived vaccine to be safe and effective while being a third of the cost of imported vaccines. India thus became the fourth country to develop an advanced hepatitis B vaccine domestically.
iet with our workout plan, and you can shed up to 8 pounds
• Lunch & Dinner Ii is a municipality of Finland. It is situated by the Bothnian Bay, at
the mouth of river Iijoki, and it is part of the Northern Ostrobothnia region. The municipality has ... • Snacks the yeast vector PMA-56. The recombinant plasmid is inserted into yeast cells. The transformed yeast cells arc multiplied in trytophan-free medium. The transformed cells are selected. The cloned yeast cells are culture for expression of HBsAg gene. This inserted gene sequence expresses and produces particles similar to the 22 mm particle of HBV as these particles are produced in serum of HBV patients. The expressed HBsAg particles have similarity in structure and immunogenicity with those isolated from HBV-infected cells of patients. Its high immunogenicity has made it possible to market the recombinant product as vaccine against HBV infection.
(ii) Indigenous Hepatitis-B vaccine. India's first genetically engineered
vaccine (Guni) against HBV developed by a Hyderabad based laboratory (Shantha Biotechnics Pvt. Ltd.) was launched on August 18, 1997. India is the fourth country (after the U.S.A., France and Beligum) to develop this highly advanced vaccine. The indigenous yeast-desired HBV vaccine is one third the cost of the imported vaccine. This new vaccine had undergone human clinical trials at Nizam's Institute of Medical Scie